Identification and characterization of a non-interferon antileishmanial macrophage activating factor (antileishmanial MAF).
A non-interferon lymphokine elaborated from PHA and Con A-stimulated human T-cell hybridoma, T-CEMA, has been found to activate monocyte-derived macrophages for the intracellular killing of L. donovani (antileishmanial MAF). This T-cell hybridoma derived antileishmanial MAF which has an apparent mw of 65,000 and pI of 5.3-5.6, contains neither antiviral activity nor colony stimulating activity. Furthermore, antileishmanial MAF is not neutralized by anti-MIF, anti-IFN-gamma or anti-GM-CSF antibodies.
Van Niel
A
A
Department of Medicine, Harvard Medical School, Boston, Massachusetts.
Zacks
S E
SE
David
J R
JR
Remold
H G
HG
Weiser
W Y
WY
D000818:Animals; D000911:Antibodies, Monoclonal; D002460:Cell Line; D006801:Humans; D006825:Hybridomas / Q000032:analysis; D007526:Isoelectric Point; D007893:Leishmania donovani / Q000187:drug effects / Q000276:immunology*; D008222:Lymphokines / Q000302:isolation & purification / Q000502:physiology*; D008262:Macrophage Activation / Q000187:drug effects; D008263:Macrophage Migration-Inhibitory Factors / Q000276:immunology / Q000302:isolation & purification; D013601:T-Lymphocytes / Q000032:analysis
D000911:Antibodies, Monoclonal; D008222:Lymphokines; D008263:Macrophage Migration-Inhibitory Factors